Three-year results for eylea hd® (aflibercept) injection 8 mg demonstrate continued durable vision gains and anatomic improvements with extended dosing intervals in patients with diabetic macular edema

88% of eylea hd patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study of the phase 3 photon trial presented at aao
REGN Ratings Summary
REGN Quant Ranking